Hybrid continuous reassessment method with overdose control for safer dose escalation.

Area of Science:

• Oncology
• Clinical Trial Design
• Biostatistics

Background:

• Phase 1 oncology trials prioritize treatment safety and determining acceptable toxicity levels.
• Existing dose-finding methods for estimating maximum tolerated dose (MTD) are often too conservative or permit excessive toxicity.
• Model-assisted designs offer transparency but need pre-defined rules.

Purpose of the Study:

• To develop a flexible and implementable hybrid model-based design for phase 1 oncology dose-finding studies.
• To improve the probability of selecting the MTD while balancing overdose control.
• To address limitations of existing dose-escalation methodologies.

Main Methods:

• A novel hybrid model-based design is proposed, integrating two separate models.
• The design aims to disentangle dose-escalation and overdose control mechanisms.
• The approach is designed for flexibility and ease of implementation in clinical settings.

Main Results:

• Extensive simulations demonstrate the proposed model's effectiveness.
• The hybrid design shows a high probability of accurately selecting the MTD.
• The model achieves a favorable balance between identifying the MTD and controlling for overdose.

Conclusions:

• The proposed hybrid model-based design offers a promising advancement for phase 1 oncology trials.
• This approach provides a more balanced and reliable method for dose escalation compared to existing designs.
• The flexibility and ease of implementation make it a practical tool for researchers.